Eve Health Group Limited · ASX:EVE
Eve Health — Investor Presentation (March 2026)
15 slides from Eve Health's investor presentation, Mar 26, 2026
Slide 1: Smarter Innovation, Better Delivery
S M A R T E R I N N O V AT I O N , BETTER DELIV ERY AD VA NCI NG PH ARMA CEU TICAL A ND NU TRACE UTI CAL DE LIV ERY FOR BET TER HEA LT H O UT CO MES. 2 SAS-B PAR T N ER - L ED PRODU CTS LAU NCH ED CO MME RCIA LISAT IO N S TAGE LICE NSI NG MODE L © EVE HEALTH GROUP 2026 ASX: EVE
Slide 2: Investment Highlights
Investment Highlights A capital-efficient reformulation platform built for partner-led scale Strategic Pillars Proof Points Capital-Light Model SAS-B Validation No large internal sales force — monetise through Two products validating strategy via Australia's SAS-B pathway. licensing and supply partn
Slide 3: Progress To Date
Progress To Date Q2 2025 Q4 2025 Q1 2026 Nextract Acquisition Second Product Launch Completed the purchase of Nextract and its Capital Raise Libbo for Men’s health launched in Australia solubility and formulation IP for Men's and $1.1m capital raise completed. under SAS(B) Women's Health Libbo Patie
Slide 4: Two Products Proving the Platform
Two Products Proving the Platform Proof-of-concept for Eve's reformulation strategy. Long-term monetisation through licensing and supply. WOMEN’S HEALTH MEN’S HEALTH Rapid-delivery oral film formulation of vardenafil Fast-acting, non-hormonal treatment for for improved speed of onset, convenience an
Slide 5: SAS(B) Validation Model
SAS(B) Validation Model Validation infrastructure de-risking partner deployment. 1 2 3 4 5 Patient Telehealth SAS-B Pharmacy Home Education Consult Prescription Fulfilment Delivery reclaimthecycle.com hubMed When clinically Chemist2U Direct to stiffissue.com TeleDocs Clinic appropriate. infrastructu
Slide 6: Proprietary Technology Platform
Proprietary Technology Platform A reformulation engine built for partner-led commercialisation API Compound Improved Delivery Faster onset, higher bioavailability. Proven active pharmaceutical ingredient. Reformulation Partner Deployment Proprietary solubility enhancement technology. License or supp
Slide 7: Capital-Light Commercial Model
Capital-Light Commercial Model From reformulation to partner-led revenue 1 2 3 4 5 Identify Reformulate Validate Register Partner High-Value API via Platform via SAS-B Product Deployment Select proven Apply proprietary Pilot commercialisation Full regulatory License or supply compounds with large so
Slide 8: Two Large, Underserved Markets
Two Large, Underserved Markets Significant unmet need in both therapeutic areas WOMEN’S HEALTH MEN’S HEALTH ~80% >40% ~50% 50% Global dysmenorrhoea Patients stop purchasing NSAID discontinuation rate Global ED prevalence prevalence PDE5Is (age 40+) 1 in 7 USD 10.9B 322m USD 5.3B Australian women are
Slide 9: R&D Pipeline Underway
R&D Pipeline Underway Future EVE Drug Reformulation Targets Name Sale Expiry Eliquis (Apixaban) $12.2B 2026 Biktarvy (Bictegravir) $11.9B 2033 Xarelto (Rivaroxaban) $6.8B 2025 Xtandi (Enzalutamide) $6.3B 2027 Farxiga (Dapagliflozin) $6.0B 2025 Imbruvica (Ibrutinib) $4.9B 2027 Total Market Value $48.
Slide 10: Key Milestones & Catalysts
Key Milestones & Catalysts Near-term value drivers over next 12 months Upcoming Milestones Commencement of BE Study for Libbo which is an integral requirement of ARTG Q2 2026 registration. First Licensing and marketing partners for Libbo and Dyspro secured. Small Batch manufacture for BE Study of PE
Slide 11: Strategic Timeline to Scalable Revenue
Strategic Timeline to Scalable Revenue From Pipeline to Commercialisation — translating validated reformulation candidates into licensing and supply partnerships. 1 2 3 4 Reformulation Regulatory Regulatory Demand Engine Advancement Advancement Validation Continuously identify, Progress products Dep
Slide 12: Corporate Snapshot
Corporate Snapshot Streamlined structure, experienced leadership Snapshot ASX Ticker EVE Share Price (Mar 2026) A$0.020 Shares on Issue 352m (83.33m escrowed until 12 June 2026) Market Capitalisation (23 Sept 2025) A$7.04m Cash A$1.9m Enterprise Value A$8.94m Board Role Rodney Hannington Non-Executi
Slide 13: Patient & Societal Impact
Patient & Societal Impact Making a difference where it matters Improved Access Faster Relief Better Quality of Life Telehealth distribution increases treatment Rapid-onset formulations dramatically Addressing widespread dissatisfaction accessibility across underserved improve patient experience and
Slide 14: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation has been prepared by and issued by Eve Health Group Limited to assist in informing interested parties about the Company and its progress. It should not be considered as an offer or invitation to subscribe for or purchase any securities in the Company
Slide 15: Smarter Innovation, Better Delivery
S M A R T ER I N N O VAT IO N , BETTER DELIV ERY 1/245 Churchill Ave, Subiaco WA 6008 +61 8 6465 5500 e: info@evehealthgroup.com.au w: www.evehealthgroup.com.au © EVE HEALTH GROUP 2026
Eve Health Group — Investor Presentation (March 2026) on 6ix